Variant histology nodular lymphocyte predominant Hodgkin lymphoma – a route to transformation?

Szychot, Elwira; Shankar, Ananth; Haider, Aiman; Ramsay, Alan D.

doi:10.1111/bjh.14607

Cited by 2 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MacLenan и соавт., выделяют два подварианта нодулярного склероза: I тип -со смешанно-клеточным составом нодулей, II тип -с лимфоидным истощением в нодулях [6]. Нодулярная ЛХ с лимфоидным преобладанием выделена в отдельную нозологическую форму [7]. Подразделение на гистологические варианты имеет большое прогностическое значение.…”

Section: Introductionunclassified

Отдаленные Результаты Лечения Пациентов С Классической Лимфомой Ходжкина В Реальной Клинической Практике: Опыт Гематологического Отделения Новосибирска

Войтко,

Поспелова,

Нечунаева

et al. 2024

Clinical Oncohematology

View full text Add to dashboard Cite

Aim. To assess the long-term results of classical Hodgkin’s lymphoma (cHL) treatment in Novosibirsk in real-world clinical practice. Materials & Methods. The study enrolled 408 cHL patients treated and followed-up at the hematological unit of the Novosibirsk Municipal Clinical Hospital No. 2 from January 2008 to December 2021. The median age of patients was 33 years (range 26–44 years). Among them 223 (54.7 %) female and 185 (45.3 %) male patients. There were more patients with cHL stages III (n = 103; 25.2 %) and IV (n = 120; 29.4 %) than with stage II, which was identified in 185 (45.4 %) patients. ABVD regimen was administered to 132 (32.3 %) patients, 47 (11.5 %) patients received ABVD escalated to BEACOPP. BEACOPP therapy was performed in 229 (56.2 %) patients. Subsequent radiotherapy was assigned to 202 (49.5 %) patients. Second-line therapy was required by 89 (21.8 %) patients with relapsed and resistant cHL. Results. The 10-year overall survival (OS) was 81 %, and the 5-year OS was 91 %. Similar progression-free survival (PFS) rates were 86 % and 77 %, respectively. The 10-year PFS in patients with stage II was 87 %, while in patients with stages II (mediastinal bulky mass), III and IV, it was only 69 % (p = 0.002). The 10-year OS in patients with localized stages was 91 %, and in patients with generalized stages it was 79 % (p = 0.0006). The 10-year OS in patients less than 45 years of age was 88 %, and in patients more than 45 years of age it was 69 %. The 10-year PFS in patients less than 45 years of age was 84 %, and in the older age group it was 60 % (p = 0.001). Conclusion. The study results demonstrate high rates of long-term survival of cHL patients and are well comparable with the data of other study groups. Nevertheless, scientific research should be continued to develop optimal risk-adapted programs of cHL chemotherapy and to define further prospects for improving the treatment outcomes of this malignant tumor.

show abstract

Section: Introductionunclassified

Отдаленные Результаты Лечения Пациентов С Классической Лимфомой Ходжкина В Реальной Клинической Практике: Опыт Гематологического Отделения Новосибирска

Войтко,

Поспелова,

Нечунаева

et al. 2024

Clinical Oncohematology

View full text Add to dashboard Cite

show abstract

Transformed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Histologic Features and Relationship to T-Cell/Histiocyte–Rich Large B-Cell Lymphoma

Alqaidy,

Kallen,

Singh

et al. 2019

AJSP: Reviews and Reports

View full text Add to dashboard Cite

Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an uncommon variant of Hodgkin lymphoma, with a generally indolent course in low-stage presentations. Recurrences can demonstrate features of the diffuse variant, resembling T-cell/histiocyte–rich large B-cell lymphoma (THRLBCL). Transformation can additionally occur, either THRLBCL-like lesion or a diffuse large B-cell lymphoma (DLBCL). Transformation to DLBCL may be detected concurrently with NLPHL, prior to NLPHL, or years to decades later. The prognosis of such transformation is controversial, but thought to be worse than NLPHL and similar to that of de novo DLBCL. T-cell/histiocyte–rich large B-cell lymphoma–like transformation is histologically indistinguishable from primary THRLBCL, reflecting significant histologic and genetic overlap between NLPHL and THRLBCL. We present a patient with NLPHL and transformation to DLBCL at 7 years after initial diagnosis, who ultimately developed a therapy-related myeloid neoplasm. We review the histologic spectrum of transformed NLPHL, its relationship with THRLBCL, and recent developments in its molecular pathogenesis. Cases of transformation may prove valuable in understanding complex biologic relationships between a spectrum of overlapping lymphoma entities and may ultimately help refine therapy and improve prognosis.

show abstract

Variant histology nodular lymphocyte predominant Hodgkin lymphoma – a route to transformation?

Cited by 2 publications

References 10 publications

Отдаленные Результаты Лечения Пациентов С Классической Лимфомой Ходжкина В Реальной Клинической Практике: Опыт Гематологического Отделения Новосибирска

Отдаленные Результаты Лечения Пациентов С Классической Лимфомой Ходжкина В Реальной Клинической Практике: Опыт Гематологического Отделения Новосибирска

Transformed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: Histologic Features and Relationship to T-Cell/Histiocyte–Rich Large B-Cell Lymphoma

Contact Info

Product

Resources

About